Efficacy of intra-arterial infusion therapy using a combination of cisplatin and docetaxel for recurrent head and neck cancers compared with cisplatin alone

Hidetake Yabuuchi, Toshiro Kuroiwa, Tsuyoshi Tajima, Kichinobu Tomita, Noriko Ochiai, Kenji Kawamoto

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aims: To compare the initial effect and toxicity, response duration and survival time of intra-arterial infusion therapy using a combination of cisplatin (CDDP) and docetaxel (DXT) with those using CDDP alone for treatment of recurrent head and neck cancers. Materials and methods: Twenty-nine patients with recurrent head and neck cancers were treated using intra-arterial infusion chemotherapy. The chemotherapeutic regimens consisted of CDDP alone (n=12) or a combination of CDDP and DTX (n= 17). In the CDDP-DTX group, both CDDP 70 mg/m2 and DTX 60 mg/m2 were administrated via the external carotid artery (ECA) or via branches of the ECA or subclavian artery. In the CDDP-alone group, CDDP 70 mg/m2 was infused. The tumour response (response rate = complete response + partial response) and toxicities (World Health Organization [WHO] classification grades 3 and 4) were evaluated in both groups and compared by Fisher's exact probability test. Results: The response rates in the CDDP-DTX group and the CDDP-alone group were 71% (12/17) and 50% (6/12), respectively (P=0.44). Leucocytopenia and neutropenia (grades 3 and 4) were significantly more prevalent in the former than in the latter group (11/17 vs 1/12; 10/17 vs 1/12) (P<0.01). However, there were no infectious diseases in any of the patients. Conclusion: Combined cisplatin-docetaxel intra-arterial infusion therapy was shown to be effective and safe for recurrent head and neck cancers.

Original languageEnglish
Pages (from-to)467-472
Number of pages6
JournalClinical Oncology
Volume15
Issue number8
DOIs
Publication statusPublished - Dec 2003

Fingerprint

docetaxel
Intra Arterial Infusions
Head and Neck Neoplasms
Cisplatin
External Carotid Artery
Subclavian Artery
Leukopenia
Neutropenia
Communicable Diseases
Therapeutics
Drug Therapy
Survival
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Efficacy of intra-arterial infusion therapy using a combination of cisplatin and docetaxel for recurrent head and neck cancers compared with cisplatin alone. / Yabuuchi, Hidetake; Kuroiwa, Toshiro; Tajima, Tsuyoshi; Tomita, Kichinobu; Ochiai, Noriko; Kawamoto, Kenji.

In: Clinical Oncology, Vol. 15, No. 8, 12.2003, p. 467-472.

Research output: Contribution to journalArticle

Yabuuchi, Hidetake ; Kuroiwa, Toshiro ; Tajima, Tsuyoshi ; Tomita, Kichinobu ; Ochiai, Noriko ; Kawamoto, Kenji. / Efficacy of intra-arterial infusion therapy using a combination of cisplatin and docetaxel for recurrent head and neck cancers compared with cisplatin alone. In: Clinical Oncology. 2003 ; Vol. 15, No. 8. pp. 467-472.
@article{55d8cff92583448a86c444815e0d730b,
title = "Efficacy of intra-arterial infusion therapy using a combination of cisplatin and docetaxel for recurrent head and neck cancers compared with cisplatin alone",
abstract = "Aims: To compare the initial effect and toxicity, response duration and survival time of intra-arterial infusion therapy using a combination of cisplatin (CDDP) and docetaxel (DXT) with those using CDDP alone for treatment of recurrent head and neck cancers. Materials and methods: Twenty-nine patients with recurrent head and neck cancers were treated using intra-arterial infusion chemotherapy. The chemotherapeutic regimens consisted of CDDP alone (n=12) or a combination of CDDP and DTX (n= 17). In the CDDP-DTX group, both CDDP 70 mg/m2 and DTX 60 mg/m2 were administrated via the external carotid artery (ECA) or via branches of the ECA or subclavian artery. In the CDDP-alone group, CDDP 70 mg/m2 was infused. The tumour response (response rate = complete response + partial response) and toxicities (World Health Organization [WHO] classification grades 3 and 4) were evaluated in both groups and compared by Fisher's exact probability test. Results: The response rates in the CDDP-DTX group and the CDDP-alone group were 71{\%} (12/17) and 50{\%} (6/12), respectively (P=0.44). Leucocytopenia and neutropenia (grades 3 and 4) were significantly more prevalent in the former than in the latter group (11/17 vs 1/12; 10/17 vs 1/12) (P<0.01). However, there were no infectious diseases in any of the patients. Conclusion: Combined cisplatin-docetaxel intra-arterial infusion therapy was shown to be effective and safe for recurrent head and neck cancers.",
author = "Hidetake Yabuuchi and Toshiro Kuroiwa and Tsuyoshi Tajima and Kichinobu Tomita and Noriko Ochiai and Kenji Kawamoto",
year = "2003",
month = "12",
doi = "10.1016/j.clon.2003.07.003",
language = "English",
volume = "15",
pages = "467--472",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Efficacy of intra-arterial infusion therapy using a combination of cisplatin and docetaxel for recurrent head and neck cancers compared with cisplatin alone

AU - Yabuuchi, Hidetake

AU - Kuroiwa, Toshiro

AU - Tajima, Tsuyoshi

AU - Tomita, Kichinobu

AU - Ochiai, Noriko

AU - Kawamoto, Kenji

PY - 2003/12

Y1 - 2003/12

N2 - Aims: To compare the initial effect and toxicity, response duration and survival time of intra-arterial infusion therapy using a combination of cisplatin (CDDP) and docetaxel (DXT) with those using CDDP alone for treatment of recurrent head and neck cancers. Materials and methods: Twenty-nine patients with recurrent head and neck cancers were treated using intra-arterial infusion chemotherapy. The chemotherapeutic regimens consisted of CDDP alone (n=12) or a combination of CDDP and DTX (n= 17). In the CDDP-DTX group, both CDDP 70 mg/m2 and DTX 60 mg/m2 were administrated via the external carotid artery (ECA) or via branches of the ECA or subclavian artery. In the CDDP-alone group, CDDP 70 mg/m2 was infused. The tumour response (response rate = complete response + partial response) and toxicities (World Health Organization [WHO] classification grades 3 and 4) were evaluated in both groups and compared by Fisher's exact probability test. Results: The response rates in the CDDP-DTX group and the CDDP-alone group were 71% (12/17) and 50% (6/12), respectively (P=0.44). Leucocytopenia and neutropenia (grades 3 and 4) were significantly more prevalent in the former than in the latter group (11/17 vs 1/12; 10/17 vs 1/12) (P<0.01). However, there were no infectious diseases in any of the patients. Conclusion: Combined cisplatin-docetaxel intra-arterial infusion therapy was shown to be effective and safe for recurrent head and neck cancers.

AB - Aims: To compare the initial effect and toxicity, response duration and survival time of intra-arterial infusion therapy using a combination of cisplatin (CDDP) and docetaxel (DXT) with those using CDDP alone for treatment of recurrent head and neck cancers. Materials and methods: Twenty-nine patients with recurrent head and neck cancers were treated using intra-arterial infusion chemotherapy. The chemotherapeutic regimens consisted of CDDP alone (n=12) or a combination of CDDP and DTX (n= 17). In the CDDP-DTX group, both CDDP 70 mg/m2 and DTX 60 mg/m2 were administrated via the external carotid artery (ECA) or via branches of the ECA or subclavian artery. In the CDDP-alone group, CDDP 70 mg/m2 was infused. The tumour response (response rate = complete response + partial response) and toxicities (World Health Organization [WHO] classification grades 3 and 4) were evaluated in both groups and compared by Fisher's exact probability test. Results: The response rates in the CDDP-DTX group and the CDDP-alone group were 71% (12/17) and 50% (6/12), respectively (P=0.44). Leucocytopenia and neutropenia (grades 3 and 4) were significantly more prevalent in the former than in the latter group (11/17 vs 1/12; 10/17 vs 1/12) (P<0.01). However, there were no infectious diseases in any of the patients. Conclusion: Combined cisplatin-docetaxel intra-arterial infusion therapy was shown to be effective and safe for recurrent head and neck cancers.

UR - http://www.scopus.com/inward/record.url?scp=0345688178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345688178&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2003.07.003

DO - 10.1016/j.clon.2003.07.003

M3 - Article

C2 - 14690002

AN - SCOPUS:0345688178

VL - 15

SP - 467

EP - 472

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 8

ER -